BTAI fundamentals
An in-depth look to BioXcel Therapeutics, Inc. operating, investing, and financing activities
BTAI free cash flow for Q1 24 is -17.71 M USD. For 2023, BTAI free cash flow was -155.03 M USD and operating cash flow was -155.01 M USD.
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
TTM